This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) (CRUISE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00485836
First received: June 11, 2007
Last updated: April 10, 2017
Last verified: April 2017
Results First Received: August 16, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Investigator;   Primary Purpose: Treatment
Conditions: Macular Edema
Retinal Vein Occlusion
Interventions: Drug: Sham injection
Drug: Ranibizumab injection 0.3 mg
Drug: Ranibizumab injection 0.5 mg

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Please note that although the table below is titled "Overall Study," the completion rates are for the 6-month Treatment Period only (i.e., does not include the 6-month Observation Period data).

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Sham Injection Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Ranibizumab Injection 0.3 mg Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Ranibizumab Injection 0.5 mg Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Participant Flow:   Overall Study
    Sham Injection   Ranibizumab Injection 0.3 mg   Ranibizumab Injection 0.5 mg
STARTED   130   132   130 
Received Study Drug (Safety Population)   129   132   129 
COMPLETED   115   129   119 
NOT COMPLETED   15   3   11 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Sham Injection Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Ranibizumab Injection 0.3 mg Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Ranibizumab Injection 0.5 mg Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Total Total of all reporting groups

Baseline Measures
   Sham Injection   Ranibizumab Injection 0.3 mg   Ranibizumab Injection 0.5 mg   Total 
Overall Participants Analyzed 
[Units: Participants]
 130   132   130   392 
Age 
[Units: Years]
Mean (Standard Deviation)
 65.4  (13.1)   69.7  (11.6)   67.6  (12.4)   67.6  (12.5) 
Age, Customized 
[Units: Participants]
       
< 45 years   10   5   5   20 
45 to < 65 years   50   36   46   132 
65 to < 85 years   67   80   71   218 
≥ 85 years   3   11   8   22 
Sex: Female, Male 
[Units: Participants]
Count of Participants
       
Female      58  44.6%      61  46.2%      50  38.5%      169  43.1% 
Male      72  55.4%      71  53.8%      80  61.5%      223  56.9% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months   [ Time Frame: Baseline and 6 months ]

2.  Secondary:   Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline   [ Time Frame: Baseline and 6 months ]

3.  Secondary:   Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline   [ Time Frame: Baseline and 6 months ]

4.  Secondary:   Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6   [ Time Frame: 6 months ]

5.  Secondary:   Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6   [ Time Frame: Baseline and 6 months ]

6.  Secondary:   Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6   [ Time Frame: Baseline and 6 months ]

7.  Secondary:   Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6   [ Time Frame: Baseline and 6 months ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame 6 months
Additional Description Investigators assessed the occurrence of AE/SAEs at all study visits. Summaries are for the safety-evaluable population and include events regardless of relation to study drug or location (e.g. non-study eye events are included). For each AE/SAE, the number of patients experiencing the event, not the number of occurrences of the event, is reported.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
Sham Injection Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
Ranibizumab Injection 0.3 mg Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
Ranibizumab Injection 0.5 mg Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.

Other Adverse Events
    Sham Injection   Ranibizumab Injection 0.3 mg   Ranibizumab Injection 0.5 mg
Total, Other (not including serious) Adverse Events       
# participants affected / at risk   116/129 (89.92%)   113/132 (85.61%)   111/129 (86.05%) 
Eye disorders       
Conjunctival Hemorrhage † 1       
# participants affected / at risk   43/129 (33.33%)   57/132 (43.18%)   53/129 (41.09%) 
Eye Irritation † 1       
# participants affected / at risk   6/129 (4.65%)   6/132 (4.55%)   10/129 (7.75%) 
Eye Pain † 1       
# participants affected / at risk   14/129 (10.85%)   12/132 (9.09%)   24/129 (18.60%) 
Foreign Body Sensation in Eyes † 1       
# participants affected / at risk   5/129 (3.88%)   4/132 (3.03%)   9/129 (6.98%) 
Iris Neovascularization † 1       
# participants affected / at risk   9/129 (6.98%)   2/132 (1.52%)   1/129 (0.78%) 
Macular Edema † 1       
# participants affected / at risk   11/129 (8.53%)   7/132 (5.30%)   4/129 (3.10%) 
Maculopathy † 1       
# participants affected / at risk   13/129 (10.08%)   21/132 (15.91%)   19/129 (14.73%) 
Myodesopsia † 1       
# participants affected / at risk   5/129 (3.88%)   9/132 (6.82%)   12/129 (9.30%) 
Ocular Vascular Disorder † 1       
# participants affected / at risk   0/129 (0.00%)   2/132 (1.52%)   8/129 (6.20%) 
Optic Disc Vascular Disorder † 1       
# participants affected / at risk   8/129 (6.20%)   7/132 (5.30%)   2/129 (1.55%) 
Retinal Depigmentation † 1       
# participants affected / at risk   8/129 (6.20%)   12/132 (9.09%)   10/129 (7.75%) 
Retinal Exudates † 1       
# participants affected / at risk   18/129 (13.95%)   36/132 (27.27%)   25/129 (19.38%) 
Retinal Hemorrhage † 1       
# participants affected / at risk   17/129 (13.18%)   15/132 (11.36%)   16/129 (12.40%) 
Retinal Pigmentation † 1       
# participants affected / at risk   4/129 (3.10%)   7/132 (5.30%)   2/129 (1.55%) 
Retinal Vascular Disorder † 1       
# participants affected / at risk   19/129 (14.73%)   21/132 (15.91%)   19/129 (14.73%) 
Vitreous Detachment † 1       
# participants affected / at risk   6/129 (4.65%)   1/132 (0.76%)   8/129 (6.20%) 
Vitreous Hemorrhage † 1       
# participants affected / at risk   8/129 (6.20%)   5/132 (3.79%)   7/129 (5.43%) 
Infections and infestations       
Nasopharyngitis † 1       
# participants affected / at risk   3/129 (2.33%)   8/132 (6.06%)   7/129 (5.43%) 
Investigations       
Intraocular Pressure Increased † 1       
# participants affected / at risk   5/129 (3.88%)   11/132 (8.33%)   11/129 (8.53%) 
Vascular disorders       
Hypertension † 1       
# participants affected / at risk   8/129 (6.20%)   4/132 (3.03%)   3/129 (2.33%) 
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA (12.0)



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Medical Communications
Organization: Genentech, Inc.
phone: 800-821-8590


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00485836     History of Changes
Other Study ID Numbers: FVF4166g
Study First Received: June 11, 2007
Results First Received: August 16, 2010
Last Updated: April 10, 2017